A study involving prophylactic use of VRC in acute myeloid leukemia patients found that CYP2C19 genotype testing not only avoided prolonging hospital stays but also moderately reduced costs, and it was projected that each patient could save $ 415 in hospitalization expenses [49]. The gene discussed is CYP2C19; the disease is acute myeloid leukemia.